Felix Mensah, MD
Hematology · Indianapolis, INNPI 1508036559
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $119,765 of the $151,600 with a category attached, or 79.0%. 34 manufacturers reported payments, led by Sobi, Inc at 41.8% of the total.
Across 177 payments — averaging $856.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$63K
- Lilly USA, LLC$48K
- CTI Biopharma Corp.$26K
- Gilead$8K
- Omeros Corporation$3K
- Janssen Scientific Affairs, LLC$550
- plus $3K from 28 others
Across 38 payments — averaging $5422.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$126K
- Janssen Research & Development, LLC$41K
- E.r. Squibb & Sons, L.L.C.$20K
- Astellas Pharma Europe BV$11K
- Bristol Myers Squibb$8K
What the payments were for
- Consulting fees$13,5259%
- Speaking & faculty fees$119,76579%
- Travel & lodging$12,6738%
- Food & beverage$5,2983%
- Education$3380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sobi, Inc | 33 | $63,383 |
| Lilly USA, LLC | 37 | $48,393 |
| CTI Biopharma Corp. | 14 | $26,053 |
| Gilead | 8 | $7,556 |
| Omeros Corporation | 1 | $2,525 |
| Janssen Scientific Affairs, LLC | 4 | $550 |
| Novartis | 7 | $517 |
| Genmab U.S., Inc. | 8 | $259 |
| Legend Biotech USA Inc. | 8 | $257 |
| Incyte Corporation | 6 | $254 |
| ADC Therapeutics America, Inc. | 2 | $202 |
| Adaptive Biotechnologies Corporation | 4 | $184 |
| Janssen Research & Development, LLC | 2 | $182 |
| Johnson & Johnson | 3 | $159 |
| Syndax Pharmaceuticals, Inc. | 1 | $150 |
| Sanofi-aventis U.S. LLC | 1 | $144 |
| AstraZeneca(2 entities) | 4 | $104 |
| Astellas Pharma US Inc | 1 | $99 |
| Daiichi Sankyo Inc. | 4 | $91 |
| Tempus AI, Inc | 3 | $60 |
| Bristol Myers Squibb | 4 | $60 |
| Amgen | 3 | $59 |
| Acrotech Biopharma Inc. | 2 | $42 |
| Sanofi | 2 | $42 |
| AbbVie | 2 | $36 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| GSK | 2 | $33 |
| Morphosys, US Inc. | 2 | $33 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $32 |
| Merck | 1 | $30 |
| Stemline Therapeutics Inc. | 1 | $23 |
| Biolinerx USA, Inc. | 1 | $22 |
| Geron Corporation | 1 | $17 |
| Karyopharm Therapeutics Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in Indianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 38 | $627,259 |
| SprycelDasatinib | 12 | $155,174 |
| Posaconazole | 24 | $60,327 |
| EliquisApixaban | 26 | $15,228 |
| Acyclovir | 229 | $5,552 |
| Atovaquone | 15 | $3,013 |
| Fluconazole | 32 | $2,232 |
| Celecoxib | 14 | $749 |
| Potassium Chloride | 30 | $585 |
| Pantoprazole Sodium | 63 | $455 |
| Azithromycin | 11 | $431 |
| Ursodiol | 14 | $408 |
| Prochlorperazine Maleate | 22 | $293 |
| Gabapentin | 13 | $279 |
| Klor-Con M20Potassium Chloride | 13 | $278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $254 | $627,25938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Indianaon file to place this against a meaningful peer group, so we don't.
Other hematology in Indianapolis
- Rafat AbonourIndianapolis$712K
- Luke AkardIndianapolis$358K
- Brandon HardestyIndianapolis$72K
- Lalitha NayakIndianapolis$11K
- Fatemeh Ardeshir LarijaniIndianapolis$3K
- Varun MittalIndianapolis$363
- Jennifer SchwartzIndianapolis$108
- Kenneth OforiIndianapolis$51
- Rakesh MehtaIndianapolis$13
- Sherif FaragKokomo$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.